Genetic Testing Falls Flat in Large Patient Drug Trials
By Susan Young,
MIT Technology Review
| 11. 19. 2013
In recent years, DNA variants in two different genes have been linked to how much blood thinner a patient needs. Researchers have developed algorithms to predict a proper dose based on those genes as well characteristics such as weight and age. But now new research suggests these formulas may not actually help doctors determine the right dose.
Blood thinners can be difficult to prescribe because each patient can respond differently depending on their physical characteristics, their diet, and other medications they take. Based on that information, doctors tailor the dosage so it is high enough to prevent clotting but not so high that it causes internal bleeding. Once an initial dose is given, blood tests can help a doctor tune in to the best dose.
The hope has been that doctors might be better able to hit the right dose by looking at genes known to affect a patient’s response to the drugs—an approach called pharmacogenetics. Many experts have promoted this approach and some small patient trials have offered hope, writes
Bruce Furie, a Harvard specialist in bleeding and...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...